KR930021177A - Pharmaceutical compositions containing HBNF and / or MK and methods of inhibiting the infectivity of viruses, and methods of preventing or treating viral infections. - Google Patents

Pharmaceutical compositions containing HBNF and / or MK and methods of inhibiting the infectivity of viruses, and methods of preventing or treating viral infections. Download PDF

Info

Publication number
KR930021177A
KR930021177A KR1019930007035A KR930007035A KR930021177A KR 930021177 A KR930021177 A KR 930021177A KR 1019930007035 A KR1019930007035 A KR 1019930007035A KR 930007035 A KR930007035 A KR 930007035A KR 930021177 A KR930021177 A KR 930021177A
Authority
KR
South Korea
Prior art keywords
virus
methods
infectivity
inhibiting
viral infection
Prior art date
Application number
KR1019930007035A
Other languages
Korean (ko)
Inventor
마아크 베커어 조오지프
로버트 오스트란더 마이클
Original Assignee
알퐁스 아아르 노에
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/874,848 external-priority patent/US5461029A/en
Priority claimed from JP4163026A external-priority patent/JP2743983B2/en
Application filed by 알퐁스 아아르 노에, 아메리칸 사이아나밋드 캄파니 filed Critical 알퐁스 아아르 노에
Publication of KR930021177A publication Critical patent/KR930021177A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)

Abstract

이 발명은 피검자에 있어서 비루스의 감염능력을 억제하는 방법을 제공한다.This invention provides the method of suppressing the infectivity of the virus in a subject.

또한 피검자에 있어서 비루스성 감염의 예방 또는 치료 방법을 제공한다.Also provided is a method for preventing or treating a viral infection in a subject.

상기 방법들은 제각기 HBNK, MK, 또는 둘의 조합물을 함유한 조성물을 활용한다.The methods utilize compositions that each contain HBNK, MK, or a combination of the two.

Description

HBNF 및/또는 MK를 함유한 제약학적 조성물 및 이를 이용한 비루스의 감염능력을 억제하는 방법 및 비루스성 감염의 예방 또는 치료방법.Pharmaceutical compositions containing HBNF and / or MK and methods of inhibiting the infectivity of viruses, and methods of preventing or treating viral infections.

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도(또한 서열 일람표 1참조), 사람 MK 유전자의 뉴클레오리드 및 아미노산 서열, 굵은 활자의 아미노산은 예측된 단백질 서열을 나타내고, 화살표는 성숙 단백질의 예측된 N-말단을 나타내며, 생쥐 게놈 DNA 프로브(probe)를 증폭 하기위해 사용된 프라이머 1 및 2에 상응하는 2개의 펩티드 서열에 밑줄을 쳤다. 유전자의 3'말단근처의 2개의 폴리아데닐화 서열에 밑줄을 쳤다.Figure 1 (see also Sequence Listing 1), the nucleotide and amino acid sequences of the human MK gene, the amino acids in bold, indicate the predicted protein sequence, the arrows indicate the predicted N-terminus of the mature protein, and the mouse genomic DNA The two peptide sequences corresponding to primers 1 and 2 used to amplify the probes are underlined. Two polyadenylation sequences near the 3 'end of the gene are underlined.

제2도는 소의 HBNF의 부분적인, 114개의 아미노산 서열을 제시한다.2 shows a partial, 114 amino acid sequence of bovine HBNF.

Claims (9)

헤파린-결합 단백질의 존재를 특징으로 하는 비루스의 감염능력을 억제하는데 유용한, 유효량의 HBNF 및 제약학적으로 허용가능한 부형체로 구성된 제약학적 조성물.A pharmaceutical composition consisting of an effective amount of HBNF and a pharmaceutically acceptable excipient useful for inhibiting the infectivity of a virus characterized by the presence of a heparin-binding protein. 헤파린-결합 단백질의 존재를 특징으로 하는 비루스의 감염능력을 억제하는데 유용한, 유효량의 MK 및 제약학적으로 허용가능한 부형제로 구성된 제약학적 조성물.A pharmaceutical composition consisting of an effective amount of MK and a pharmaceutically acceptable excipient, useful for inhibiting the infectivity of a virus characterized by the presence of a heparin-binding protein. 헤파린-결합 단백질의 존재를 특징으로 하는 비루스의 감염능력을 억제하는데 유용한, 유효량의 HBNF 및 MK, 및 제약학적으로 허용가능한 부형체로 구성된 제약학적 조성물.A pharmaceutical composition comprising an effective amount of HBNF and MK, and a pharmaceutically acceptable excipient, useful for inhibiting the infectivity of a virus characterized by the presence of a heparin-binding protein. 제1내지 제3항에 있어서, 비루스가 헤르패스비리데비루스(Herpesviridae virus)인 제약학적 조성물.The pharmaceutical composition of claim 1, wherein the virus is Herpesviridae virus. 헤파린-결합 단백질의 존재를 특징으로 하는 비루스에 대한 세포성 수용기 또는 상기 비루스의 수용체-결합 단백질을 유효량의 제1 내지 제3항의 조성물과 접촉시키는 것으로 구성된, 비루스의 감염능력을 억제하는 방법.A method of inhibiting the infectivity of a virus comprising consisting of contacting a cellular receptor for the virus or a receptor-binding protein of the virus with an effective amount of the composition of claims 1 to 3 characterized by the presence of a heparin-binding protein. 헤파린-결합 단백질의 존재를 특징으로 하는 비루스에 의한 피검자의 비루스성 감염을 예방하기에 효과적인, 유효량의 제1 내지 3항의 제약학적 조성물을 피검자에게 투여하는 것으로 구성된, 피검자에 있어서 상기 비루스성 감염 예방방법.Preventing said viral infection in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claims 1 to 3 effective for preventing the viral infection of the subject by the virus characterized by the presence of a heparin-binding protein. Way. 제5또는 제6항에 있어서, 비루스성 감염이 헤르패스 비리데 비루스성 감염인 방법.The method of claim 5 or 6, wherein the viral infection is a herpes viride virus. 헤파린-결합 단백질의 존재를 특징으로 하는 비루스에 의한 비루스성 감염을 치료하기에 효과적인, 유효량의 제1 내지 제3항의 제약학적 조성물을 피검자에게 투여하는 것으로 구성된, 피검자에 있어서 비루스성 감염 치료방법.A method of treating a viral infection in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claims 1 to 3, which is effective for treating the viral infection caused by the virus characterized by the presence of a heparin-binding protein. 제8항에 있어서, 비루스성 감염이 헤르페스 비리데 비루스성 감염인 방법.The method of claim 8, wherein the viral infection is a herpes viride viral infection. ※ 참고사항: 최초출원 내용에 의하여 공개하는 것임※ Note: The disclosure is based on the initial application.
KR1019930007035A 1992-04-24 1993-04-23 Pharmaceutical compositions containing HBNF and / or MK and methods of inhibiting the infectivity of viruses, and methods of preventing or treating viral infections. KR930021177A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/874,848 1992-04-24
US07/874,848 US5461029A (en) 1992-04-24 1992-04-24 Method of treating herpes viral infections using HBNF and MK proteins
JP92-163026 1992-06-22
JP4163026A JP2743983B2 (en) 1992-06-22 1992-06-22 Illumination device and projection type image display device

Publications (1)

Publication Number Publication Date
KR930021177A true KR930021177A (en) 1993-11-22

Family

ID=67137246

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930007035A KR930021177A (en) 1992-04-24 1993-04-23 Pharmaceutical compositions containing HBNF and / or MK and methods of inhibiting the infectivity of viruses, and methods of preventing or treating viral infections.

Country Status (1)

Country Link
KR (1) KR930021177A (en)

Similar Documents

Publication Publication Date Title
Rueda et al. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles
RU2305560C2 (en) Vaccine formula against bovine respiratory pathologies
Sen et al. The genome-associated, specific RNA binding proteins of avian and mammalian type C viruses
Vey et al. Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediatedby the human endoprotease furin
DE69330372T2 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH HEPATITIS C VIRUSES
Donson et al. The nucleotide sequence of a geminivirus from Digitaria sanguinalis
WO1993020207A1 (en) Use of restriction endonucleases against viruses, including hiv
BR9812232A (en) Human respiratory syncytial virus (rsv) human subgroup b, isolated, recombinantly generated, attenuated, vaccine, process to immunize an individual to induce protection against rsv subgroup b, composition, process to produce attenuated infectious rsv subgroup b, and isolated acid molecule nucleic
EP2149583B1 (en) Modified VP1-capsid protein of parvovirus B19
Li et al. Characterization of cell-binding properties of bovine herpesvirus 1 glycoproteins B, C, and D: identification of a dual cell-binding function of gB
KR900013984A (en) Use of functional derivatives of intercellular adhesion molecule ICAM-1 for antiviral therapy
BR0111366A (en) Recombinant Porcine Respiratory and Respiratory Syndrome Virus (prrsv) Vaccine
HOVANESSIAN et al. Lack of systematic correlation between the interferon mediated antiviral state and the levels of 2-5A synthetase and protein kinase in three different types of murine cells
BR9803960A (en) D-sorbitol dehydrogenase gene.
BR9811592A (en) Cytokinin oxidase
US5800981A (en) Human cytomegalovirus antigen and its use
WO1991016925A1 (en) Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines
Fernandes et al. Binding of reovirus to receptor leads to conformational changes in viral capsid proteins that are reversible upon virus detachment.
BR9815285A (en) Alphaviruses for paramyxoviruses vaccine
AR005750A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT OR PREVENT ZOSTER INFECTIONS IN PERSONS INFECTED WITH THE VARICELA ZOSTER VIRUS AND PROCEDURE FOR PREPARING SUCH COMPOSITION
KR930021177A (en) Pharmaceutical compositions containing HBNF and / or MK and methods of inhibiting the infectivity of viruses, and methods of preventing or treating viral infections.
Lyaku et al. The distinction of serologically related ruminant alphaherpesviruses by the polymerase chain reaction (PCR) and restriction endonuclease analysis
SK283446B6 (en) Isolated DNA variant, host cell, method for production of homogeneous gp350 protein, pharmaceutical composition containing it and use
US5843724A (en) Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
AU1695900A (en) Antiviral peptides

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination